AFL:NYSEAFLAC Incorporated Analysis
Data as of 2026-05-25 - not real-time
$117.86
Latest Price
3/10Risk
Risk Level: Low
Executive Summary
Aflac’s stock is trading at $117.86, comfortably above its 20‑day ($115.60), 50‑day ($112.62) and 200‑day ($110.60) simple moving averages, confirming a bullish technical backdrop. The MACD line sits at 1.35 above its signal at 1.18, delivering a bullish histogram, while the RSI of 61.8 signals strength without being overbought. With a beta near 0.13 and 30‑day volatility of roughly 14.4%, the equity exhibits low market‑risk sensitivity, and the price is supported at $109.55 with resistance near $119.81. On the fundamentals side, the company posts a 27.9% revenue growth rate, a solid 29.6% operating margin, and a 16.5% ROE, all while trading at a forward‑PE of 15.5 versus an industry average of 16.8, indicating relative cheapness. The dividend yield of 2.07% is backed by a modest 27% payout ratio and robust free cash flow, supporting sustainability. Overall, the blend of bullish technical signals and attractive valuation metrics positions AFL as a potential upside play.
However, recent analyst activity has been mixed, with Piper Sandler lowering its price target after a quarterly miss and insiders selling $4.9 M of stock, injecting some caution. Despite this, the dividend narrative remains strong, and the company’s diversified exposure across the U.S. and Japan provides a balanced geographic profile. Investors should weigh the short‑term price proximity to resistance against the longer‑term fundamentals and dividend appeal.
However, recent analyst activity has been mixed, with Piper Sandler lowering its price target after a quarterly miss and insiders selling $4.9 M of stock, injecting some caution. Despite this, the dividend narrative remains strong, and the company’s diversified exposure across the U.S. and Japan provides a balanced geographic profile. Investors should weigh the short‑term price proximity to resistance against the longer‑term fundamentals and dividend appeal.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near short‑term resistance at $119.81
- Bullish MACD and RSI indicating momentum
- Recent analyst downgrades and insider sales
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued relative to peers (PE 13.5 vs 16.8 industry)
- Strong revenue growth and operating margins
- Sustainable dividend with low payout ratio
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Consistent cash flow generation supporting dividend growth
- Diversified geographic exposure (U.S. and Japan)
- Low beta and modest volatility reducing market risk
Key Metrics & Analysis
Financial Health
Revenue Growth27.90%
Profit Margin25.60%
P/E Ratio13.5
ROE16.47%
ROA3.09%
Debt/Equity48.28
P/B Ratio2.0
Op. Cash Flow$2.9B
Free Cash Flow$4.9B
Industry P/E16.8
Technical Analysis
TrendBullish
RSI61.8
Support$109.55
Resistance$119.81
MA 20$115.60
MA 50$112.62
MA 200$110.60
MACDBullish
VolumeDecreasing
Fear & Greed Index91.61
Valuation
Fair Value$331.87
Target Price$112.07
Upside/Downside-4.91%
GradeUndervalued
TypeBlend
Dividend Yield2.07%
Risk Assessment
Beta0.13
Volatility14.44%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.